Company intelligence / Profile preview

HOX Therapeutics

Guildford*, England or Surrey*, United Kingdomhoxtherapeutics.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

HOX Therapeutics is a preclinical-stage biotechnology company developing highly targeted medicines for the treatment of cancer. The company has announced collaborations to identify small molecule inhibitors against undisclosed oncology targets but has not yet reported clinical results.

No clinical data available as all programs are in preclinical stages.

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Drug pipeline

2 assets

Hox-PBX binding inhibitor

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Vernalis (R&D) Ltd / HitGen Inc. – Collaboration to identify inhibitors against an undisclosed oncology target using fragment-based drug discovery platforms.

Beyond the preview

Go deeper on HOX Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HOX Therapeutics.

Explore the full profile